Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.
Authors: Ozer BH; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Cohen AL; Division of Oncology, Huntsman Cancer Institute, Salt Lake City, Utah, USA., Colman H; Department of Neurosurgery, Huntsman Cancer Institute, Salt Lake City, Utah, USA., Penas-Prado M; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., de Groot J; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghin ME; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pan E; Department of Neurology and Neurotherapeutics, Division of Hematology-Oncology, University of Texas Southwestern, Dallas, Texas, USA., Raizer JJ; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Kumthekar P; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Fink KL; Department of Neurology/Neuro-Oncology, Baylor University Medical Center, Houston, Texas, USA., Walbert T; Department of Neurology and Neurosurgery, Henry Ford Health, Wayne State and Michigan State University, Detroit, Michigan, USA., Merrell RT; Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA., Groves MD; Texas Oncology, Austin Brain Tumor Center, Austin, Texas, USA., Ahluwalia MS; Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA., Wu J; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Burton EC; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Vera E; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Mendoza T; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Grajkowska E; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Wall K; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Reyes J; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Yuan Y; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Armstrong TS; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA., Gilbert MR; Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA.
Source: Neuro-oncology advances [Neurooncol Adv] 2026 Jan 23; Vol. 8 (1), pp. vdaf261. Date of Electronic Publication: 2026 Jan 23 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-2498
DOI:10.1093/noajnl/vdaf261